Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

PEMAZYRE

PEMIGATINIB

Standard Dose
13.5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview PEMAZYRE is listed in Drugs@FDA under application 213736 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient PEMIGATINIB Form and strength TABLET;ORAL - 13.5MG Sponsor INCYTE CORP Submission history Latest submission status date: 2022-08-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview PEMAZYRE is listed in Drugs@FDA under application 213736 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient PEMIGATINIB Form and strength TABLET;ORAL - 13.5MG Sponsor INCYTE CORP Submission history Latest submission status date: 2022-08-26 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.